Goldman Sachs
VCNX

Goldman Sachs’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Goldman Sachs’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-107
Closed -$24K – 6599
2022
Q2 		$24K Buy
+107
New +$27.3K ﹤0.01% 6149
2021
Q3 		– Sell
-102
Closed -$60K – 6573
2021
Q2 		$60K Buy
102
+5
+5% +$2.64K ﹤0.01% 6045
2021
Q1 		$61K Sell
97
-71
-42% -$45.6K ﹤0.01% 5916
2020
Q4 		$73K Buy
+168
New +$70.3K ﹤0.01% 5337

Other funds holding VCNX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Goldman Sachs's VCNX Position: Q3 2022 in Review

Goldman Sachs sold out of Vaccinex, Inc. Common Stock (VCNX) in Q3 2022, closing a stake of 107 shares — an estimated $24K sold.

Goldman Sachs first reported a position in VCNX in Q4 2020 and held it in 4 quarters. The position peaked at $73K in Q4 2020. 22 funds tracked by Wall St. Rank hold VCNX as of Q3 2022.

  • Goldman Sachs reported no remaining Vaccinex, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 107 Vaccinex, Inc. Common Stock shares in Q3 2022, an estimated $24K.
  • Goldman Sachs first reported a position in Vaccinex, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Goldman Sachs's Vaccinex, Inc. Common Stock position peaked at $73K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.